PER® Winter Lung Cancer Conference | Conference

Borghaei Breaks Down Choices in Immunotherapy Approaches in Lung Cancer

February 8th 2021

With the emergence of multiple immunotherapy approaches in recent years, the decision of whether to use a single agent, to pair it with chemotherapy, or to pair it with another immunotherapy agent has come to the forefront of treatment.

Dr. Brahmer on Determining When to Start Immunotherapy in Frontline NSCLC

February 8th 2021

Julie R. Brahmer, MD, discusses factors to consider when determining when to initiate immunotherapy in a patient with newly diagnosed non–small cell lung cancer.

Dr. Raez on the Potential Utility of Cemiplimab in NSCLC

February 8th 2021

Luis E. Raez, MD, discusses the potential utility of cemiplimab-rwlc in non–small cell lung cancer.

Strategizing Effective Ways to Overcome TKI Resistance in ALK+ NSCLC

February 8th 2021

Vincent Lam, MD, describes frontline indications for this patient population, as well as strategies that can be utilized to overcome TKI resistance in later lines of therapy.

Forde Recaps Chemoimmunotherapy Activity in PD-L1–Negative NSCLC

February 8th 2021

Immunotherapy plus chemotherapy is a standard of care for patients with advanced PD-L1–negative non–small cell lung cancer who do not harbor actionable driver mutations.

New Options Spark Sequencing and Biomarker Trials in Mesothelioma

February 7th 2021

Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual patients.

Future of Frontline EGFR+ NSCLC Features TKI, Chemo Combos and Improved Molecular Profiling

February 7th 2021

Synergizing EGFR TKIs with antiangiogenic agents and chemotherapy, as well as improving the use of molecular classification, are novel strategies aimed at taking the frontline setting for patients with EGFR-mutant non–small cell lung cancer to the next level.

Durvalumab Delivers Durable Benefit, Regardless of PD-L1 Expression, in NSCLC

February 7th 2021

Mark A. Socinski, MD, discusses the nuances of the PACIFIC trial and ongoing research with durvalumab that could extend the reach of immunotherapy in early-stage lung cancer.

ADAURA Raises Questions About Optimal Use of Adjuvant EGFR TKIs in NSCLC

February 6th 2021

Over the past 2 decades, the field of EGFR-mutated non–small cell lung cancer has grown tremendously, but the influx of data and the recent regulatory approval of adjuvant osimertinib have raised several important questions to be addressed to ensure that the optimal treatment approach is utilized.

Lung Cancer Paradigm Pushes Toward Accessible Care and Improved Telemedicine

February 6th 2021

Rogerio C. Lilenbaum, MD, discusses some of the key clinical issues facing the lung cancer field, the role of genomic testing and multidisciplinary care, and the challenges that arose with telemedicine during the coronavirus disease 2019 pandemic.

Experts Take Stock of Critical Clinical Issues in Lung Cancer

February 6th 2021

In the quest for scientific purity, one should not lose sight of the meaningful end points that can make a difference in patients’ daily lives.

Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung Cancer

February 6th 2021

Mary Jo J. Fidler, MD, discusses the potential utility of circulating tumor DNA to inform treatment escalation in lung cancer.

Dr. Lilenbaum on the Challenges of Integrating Telehealth Services in Lung Cancer

February 6th 2021

Rogerio C. Lilenbaum, MD, discusses the challenges of integrating telehealth services in lung cancer.

Dr. Socinski on the Role of Immunotherapy in PD-L1–Negative Lung Cancer

February 6th 2021

Mark A. Socinski, MD, discusses the role of immunotherapy in PD-L1–negative lung cancer.

Dr. Borghaei on Selecting Single-Agent Versus Combination Therapy in Lung Cancer

February 6th 2021

Hossein Borghaei, DO, MS, discusses selecting between single-agent versus combination therapies in lung cancer.

Assessing Treatment Strategies ALK+ Lung Cancer

February 11th 2020

Luis E. Raez, MD, provides insight into therapies available to patients with ALK-mutant non–small cell lung cancer and underscores the role of genetic testing in informing treatment decisions.

Dr. Wakelee on Immediate Therapy Options in Lung Cancer

February 10th 2020

Heather A. Wakelee, MD, discusses therapy options when patients with lung cancer must receive treatment options immediately rather than wait for molecular testing results.

Dr. Pennell on Benefits of Liquid Biopsies in Lung Cancer

February 10th 2020

Nathan A. Pennell, MD, PhD, discusses the benefits of liquid biopsies in lung cancer.

Brahmer Highlights Next Steps for Osimertinib in EGFR-Mutant NSCLC

February 10th 2020

Julie R. Brahmer, MD, discusses the impact of osimertinib in EGFR-mutant non–small cell lung cancer, ongoing research with the agent, and the importance of molecular testing.

Should EGFR TKI Use Expand in Frontline NSCLC?

February 10th 2020

Treatment with osimertinib in the frontline has been the standard of care for patients with EGFR-mutant non–small cell lung cancer since the pivotal FLAURA trial.